about
Protein kinase WNK3 increases cell survival in a caspase-3-dependent pathwayProtein kinase WNK2 inhibits cell proliferation by negatively modulating the activation of MEK1/ERK1/2Regulatory Crosstalk by Protein Kinases on CFTR Trafficking and Activity.Posttranscriptional Regulation of Splicing Factor SRSF1 and Its Role in Cancer Cell BiologyPCR amplification introduces errors into mononucleotide and dinucleotide repeat sequencesMixed lineage kinase 3 gene mutations in mismatch repair deficient gastrointestinal tumours.Contribution of casein kinase 2 and spleen tyrosine kinase to CFTR trafficking and protein kinase A-induced activity.Molecular mechanisms involved in cisplatin cytotoxicity.Emerging roles for WNK kinases in cancer.Protein kinase WNK1 promotes cell surface expression of glucose transporter GLUT1 by regulating a Tre-2/USP6-BUB2-Cdc16 domain family member 4 (TBC1D4)-Rab8A complex.Cisplatin inhibits synthesis of ribosomal RNA in vivoSilencing of the tumor suppressor gene WNK2 is associated with upregulation of MMP2 and JNK in gliomas.Posttranscriptional Regulation and RNA Binding Proteins in Cancer BiologyRac1 signalling modulates a STAT5/BCL-6 transcriptional switch on cell-cycle-associated target gene promotersRac1 signaling modulates BCL-6-mediated repression of gene transcription.Phosphorylation of SRSF1 by SRPK1 regulates alternative splicing of tumor-related Rac1b in colorectal cells.Beyond COX-inhibition: 'side-effects' of ibuprofen on neoplastic development and progression.The third dimension: new developments in cell culture models for colorectal research.Expression of tumor-related Rac1b antagonizes B-Raf-induced senescence in colorectal cells.Targeting the serrated pathway of colorectal cancer with mutation in BRAF.Therapeutic strategies based on modified U1 snRNAs and chaperones for Sanfilippo C splicing mutations.Loss of WNK2 expression by promoter gene methylation occurs in adult gliomas and triggers Rac1-mediated tumour cell invasiveness.Transcription initiation arising from E-cadherin/CDH1 intron2: a novel protein isoform that increases gastric cancer cell invasion and angiogenesis.Microcystin-LR activates the ERK1/2 kinases and stimulates the proliferation of the monkey kidney-derived cell line Vero-E6.Antagonistic SR proteins regulate alternative splicing of tumor-related Rac1b downstream of the PI3-kinase and Wnt pathways.B-Raf(V600E) cooperates with alternative spliced Rac1b to sustain colorectal cancer cell survival.WNK2 modulates MEK1 activity through the Rho GTPase pathway.Rac1, but not Rac1B, stimulates RelB-mediated gene transcription in colorectal cancer cells.Tumor-related alternatively spliced Rac1b is not regulated by Rho-GDP dissociation inhibitors and exhibits selective downstream signaling.The topography of chromosomes and genes in the nucleus.Targeting of adenovirus E1A and E4-ORF3 proteins to nuclear matrix-associated PML bodies.In vivo evidence that TATA-binding protein/SL1 colocalizes with UBF and RNA polymerase I when rRNA synthesis is either active or inactive.Three-way translocation involves MLL, MLLT3, and a novel cell cycle control gene, FLJ10374, in the pathogenesis of acute myeloid leukemia with t(9;11;19)(p22;q23;p13.3).Increased Rac1b expression sustains colorectal tumor cell survival.Expression of Rac1b stimulates NF-kappaB-mediated cell survival and G1/S progression.Corrigendum: Phosphorylation of SRSF1 by SRPK1 regulates alternative splicing of tumor-related Rac1b in colorectal cells.A missense mutation in the APC tumor suppressor gene disrupts an ASF/SF2 splicing enhancer motif and causes pathogenic skipping of exon 14.A WNK4 gene variant relates to osteoporosis and not to hypertension in the Portuguese population.Signaling Pathways Driving Aberrant Splicing in Cancer Cells.Small GTPase Rac1: structure, localization, and expression of the human gene.
P50
Q24305919-D2522F49-3D45-4E31-A31B-6F8FA7260F38Q24323910-D5201CA9-E6C0-4F15-9EF4-E3B697B01638Q26770258-6D592D55-9EAD-488B-B0EE-75C3D2FABBEDQ26798154-E1B9D4B9-E129-44A3-B2BA-4325B9D685F7Q28360523-1B137826-977C-49A7-BC8A-08F4A33B5804Q33594249-B3403DC0-B8C1-487E-9B07-53572D7EC369Q34022687-4003C9DC-6361-4CEA-84DB-EEC60E1C1A42Q34058522-5261867B-70A3-41C7-8659-0B8FC7DC3F1AQ34094226-B04E8AE0-EBDD-4C98-AF33-1EE6EBB78F72Q34385634-0E4EB861-3C51-4644-BA13-40A1B01B2118Q34669295-97389ABC-142B-4C76-B865-F1789EF5CB94Q35176325-168FF6C5-F2B5-41F1-AE90-B6856FDC9B3DQ35932172-6BD27FD8-109F-4AF2-9BEB-B2F170A37B0DQ36228634-CFFB2CE3-D713-47E5-B59B-A5CC38814E14Q37275178-94D97C83-8319-40E0-BC5D-950A27D16504Q37661658-2B567047-6C80-4137-AA42-A16D9B49E508Q38500489-A28C8F96-0594-4F24-B3A4-B6105F19D824Q38773122-4F23F9C3-4D0A-4BFE-B087-46D6403B90A3Q38837736-830E0B88-E881-4A94-AF85-DB0830DD4EE1Q38877555-CA5A9A18-9C90-4BFD-AAB8-BB016BFD8AF8Q39078944-F1AD04B8-1B97-4C87-B549-F0B8C015BCBAQ39266398-A1B0D38C-59CE-4486-8967-72AA6EB8329CQ39321532-103CAFFD-D1CF-407C-ADE6-A5535BA7B46BQ39690086-7CE44B45-460D-4E10-B653-77F56D570B09Q39825334-A929F7F0-4BCF-45C5-8BAE-6274BE67C161Q39964829-67CE0359-850B-4E85-8BF1-D0CFB73B0BE5Q39966485-9FF124D9-2F0B-407A-805F-70796B2BE89FQ40301555-DB58289D-68B3-4639-A7E9-87E2B8B15911Q40631985-B788EAD0-BC23-46A3-9367-BCE1D31F4BE6Q41295488-AD9DFCA4-8690-4DAE-B6EE-1F37ADF191ABQ42676601-D96BDEBD-1E1C-475F-9436-8A6CA3AA64CCQ42772100-4AE72F3E-AC7B-4C06-A8F0-C9079D50F6E3Q42805619-94C439FD-3482-40C6-9490-501FE0F8F379Q42810398-F932A94A-4393-4303-A1C9-D9B5FF97C9E7Q42816126-0CF807DE-4293-4EF2-AC24-991012857796Q43115735-691BDB94-03D3-47CB-B6CD-89BFC6201DAEQ45158736-C80D00D3-8113-43BD-B6F8-28737FC3D5D1Q46069289-A43C7CCE-E918-43E1-9AAA-A4C73684AAA3Q47246029-D9436919-126B-4592-95AA-9FA4BFB6F556Q47817251-ED2BF44E-C4E9-481A-AEB3-3739B4B8F1C2
P50
description
Molecular Oncobiologist
@en
biochemicus
@nl
name
Peter Jordan
@ast
Peter Jordan
@en
Peter Jordan
@es
Peter Jordan
@nl
type
label
Peter Jordan
@ast
Peter Jordan
@en
Peter Jordan
@es
Peter Jordan
@nl
prefLabel
Peter Jordan
@ast
Peter Jordan
@en
Peter Jordan
@es
Peter Jordan
@nl
P1053
G-9335-2012
P106
P1153
28267819400
P21
P31
P3829
P496
0000-0002-1425-9211
P569
1962-01-01T00:00:00Z